Aflibercept: A novel VEGF targeted agent to explore the future perspectives of anti-angiogenic therapy for the treatment of multiple tumors

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 4, 2013, Pages 530-540

  Sharma, Tina ^a   Dhingra, Richa ^a   Singh, Sukhminder ^a   Sharma, Shivani ^a   Tomar, Prince ^a   Malhotra, Manav ^a   Bhardwaj, T R ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Aflibercept; Angiogenesis; Chemotherapy; VEGF; VEGF Trap

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HYBRID PROTEIN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PLACEBO; PLACENTAL GROWTH FACTOR; PREDNISONE; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D;

ADENOCARCINOMA; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; BLEEDING; BREAST CANCER; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; GLIOBLASTOMA; HOARSENESS; HUMAN; HYPERTENSION; IMMUNOGENICITY; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MULTIPLE CANCER; MYALGIA; NAUSEA; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOSIS; TUMOR VASCULARIZATION; VASCULAR TUMOR;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HUMANS; NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875339336     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313040006     Document Type: Review

References (87)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N Engl J. Med., 1971, 285, 1182-1186.
2. Folkman, J.; Klagsbrun, M. Angiogenic factors. Science., 1987, 235, 442-447.
3. Zetter, BR. Angiogenesis and tumor metastasis. Ann Rev Med., 1998, 49, 407-424.
4. Tong, RT.; Boucher, Y.; Kozin, SV.; Winkler, F; Hicklin, DJ; Jain, RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res., 2004, 64, 3731-3736.5.
5. Jain, RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science., 2005, 307, 58-62.6.
6. Hida, K.; Hida, Y.; Amin, DN.; Flint, AF.; Panigrahy, D.; Morton, CC.; Klagsbrun, M. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res., 2004, 64, 8249-8255.
7. Ferrara, N. Vascular endothelial growth factor basic science and clinical progress. Endocr Rev., 2004, 25, 581-611.
8. Hicklin, DJ.; Ellis, LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol., 2005, 23, 1011-1127.
9. Li-Song, T.; Ke-Tao, J.; Kui-Feng, He.; Jing, Z.; Hao-Hao, W.; Jiang, Cao. Clinical Applications of VEGF-Trap (Aflibercept) in Cancer Treatment. J Chin Med Assoc., 2010, 73, 449-454.
10. Lohela, M.; Bry, M.; Tammela, T.; Alitalo, K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol., 2009, 21, 154-165.
11. Ellis, LM.; Hicklin, DJ. VEGF-targeted therapy: mechanisms of anti-tumour. Rev Cancer., 2008, 8, 579-591.
12. Koukourakis, GV. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question. Recent Pat Inflamm Allergy Drug Discov. 2012, 6, 70-77.
13. Hicklin, DJ.; Ellis, LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol., 2005, 23, 1011-1127.
14. Gerber, HP.; Ferrara, N. Pharmacology and pharmacodynamits of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res., 2005, 65, 671-680.
15. Zondor, SD.; Medina, PJ. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother., 2004, 38, 1258-1264.
16. Zhu, X.; Dahut, WL.; Parikh, CR.; Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis., 2007, 49, 186-193.
17. Ivy, SP.; Wick, JY.; Kaufman, BM. An overview of smallmolecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol., 2009, 6, 569-579.
18. Keefe, D.; Bowen, J.; Gibson, R.; Tan, T.; Okera, M.; Stringer, A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist., 2011, 16, 432-444.
19. Gaya, A.; Tse, V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat. Revi., 2012, 38, 484-493.
20. Wulff, C.; Wilson, H.; Wiegand, SJ.; Rudge, JS.; Fraser, HM. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology., 2002, 143, 2797-2807.
21. Kim, ES.; Serur, A.; Huang, J.; Manley, CA.; McCrudden, KW.; Frischer, JS.; Soffer, SZ.; Ring, L.; New, T.; Zabski, S.; Rudge, JS.; Holash, J.; Yancopoulos, GD.; Kandel, JJ.; Yamashiro, DJ. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA., 2002, 99, 11399-11404.
22. Holash, J.; Davis, S.; Papadopoulos, N.; Croll, SD.; Ho, L.; Russell, M.; Boland, P.; Leidich, R.; Hylton, D.; Burova, E.; Ioffe, E.; Huang, T.; Radziejewski, C.; Bailey, K.; Fandl, JP.; Daly, T.; Wiegand, SJ.; Yancopoulos, GD.; Rudge, JS. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA., 2002, 99, 11393-11398.
23. Byrne, AT.; Ross, L.; Holash, J.; Nakanishi, M.; Hu, L.; Hofmann, JI.; Yancopoulos, GD.; Jaffe, RB. Vascular endothelial growth factor-trapdecreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res., 2003, 9, 5721-5728.
24. Inai, T.; Mancuso, M.; Hashizume, H.; Baffert, F.; Haskell, A.; Baluk, P.; Hu-Lowe, DD.; Shalinsky, DR.; Thurston, G.; Yancopoulos, GD.; McDonald, DM. Inhibition of vascular endothelialgrowth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol., 2004, 165, 35-52.
25. Bergers, G.; Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer., 2008, 8, 592-603.
26. Grothey, A.; Galanis, E. Targeting angiogenesis progress with anti-VegF treatment with large molecules. Nat Rev Clin Oncol., 2009, 6, 507-518.
27. Moroney, John W.; Sood, Anil K.; Coleman, Robert L.; Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center. Future Oncol., 2009, 5, 591-600.
28. Ribatti, D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis., 2008, 11, 215-221.
29. Lockhart, AC.; Rothenberg, ML.; Dupont, J.; Cooper, W.; Chevalier, P.; Sternas, L.; Buzenet, G.; Koehler, E.; Sosman, JA.; Schwartz, LH.; Gultekin, DH.; Koutcher, JA.; Donnelly, EF.; Andal, R.; Dancy, I.; Spriggs, DR.; Tew, WP. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol., 2010, 28, 207-214.
30. Lu, JF.; Bruno, R.; Eppler, S.; Novotny, W.; Lum, B.; Gaudreault, J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol., 2008, 62, 779-86.
31. Tew, WP.; Gordon, M.; Murren, J.; Dupont, J.; Pezzulli, S.; Aghajanian, C.; Sabbatini, P.; Mendelson, D.; Schwartz, L.; Gettinger, S.; Psyrri, A.; Cedarbaum, JM.; Spriggs, DR. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res., 2010, 16, 358-366.
32. Glade Bender, J.; Blaney, SM.; Borinstein, S.; Reid, JM.; Baruchel, S.; Ahern, C.; Ingle, AM.; Yamashiro, DJ.; Chen, A.; Weigel, B.; Adamson, PC.; Park, JR. A pediatric phase I trial and pharmacokinetic study of aflibercept (VEGF Trap): A Children's Oncology Group Phase I Consortium study. J Clin Oncol., 2010, 28, 90-122.
33. Rudge, JS.; Holash, J.; Hylton, D.; Russell, M.; Jiang, S.; Leidich, R.; Papadopoulos, N.; Pyles, EA.; Torri, A.; Wiegand, SJ.; Thurston, G.; Stahl, N.; Yancopoulos, GD. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci. U.S. A, 2007, 20, 18363-18370.
34. Meyer, T.; Robles-Carrillo, L.; Robson, T.; Langer, F.; Desai, H.; Davila, M.; Amaya, M.; Francis, JL.; Amirkhosravi, A. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost., 2009, 7, 171-181.
35. Baffert, F.; Le, T.; Sennino, B.; Thurston, G.; Kuo, CJ.; Hu-Lowe, D.; McDonald, DM. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Epub., 2006, 290, 47-59.
36. Williams, JL.; Cartland, D.; Rudge, JS.; Egginton, S. VEGF trap abolishes shear stressand overload-dependent angiogenesis in skeletal muscle. Microcirculation., 2006, 13, 499-509.
37. Taylor, PD.; Wilson, H.; Hillier, SG.; Wiegand, SJ.; Fraser, HM. Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset. Mol Hum Reprod., 2007,13, 729-736.
38. Fraser HM, Wilson H, Silvestri A, Morris KD, Wiegand SJ. The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset. Endocrinology., 2008, 149, 4413-4420.
39. Fan X, Krieg S, Kuo CJ, Wiegand SJ, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC, Nayak NRFASEB J. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J, 2008, 22, 3571-3580.
40. Huang, J.; Frischer, JS.; Serur, A.; Kadenhe, A.; Yokoi, A.; McCrudden, KW.; New, T.; O'Toole, K.; Zabski, S.; Rudge, JS.; Holash, J.; Yancopoulos, GD.; Yamashiro, DJ.; Kandel, JJ. Regression of established tumors and metastases by potent vascular endothelial growth factorblockade. Proc Natl Acad Sci. U.S.A., 2003, 100, 7785-7790.
41. Byrne, AT.; Ross, L.; Holash, J.; Nakanishi, M.; Hu, L.; Hofmann, JI.; Yancopoulos, GD.; Jaffe, RB. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res., 2003, 9, 5721-5728.
42. Fukasawa, M.; Korc, M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res., 2004, 10, 3327-3332.
43. Verheul, HM.; Hammers, H.; Van Erp, K.; Wei, Y.; Sanni, T.; Salumbides, B.; Qian, DZ.; Yancopoulos, GD.; Pili, R. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res., 2007, 13, 4201-4208.
44. Gomez-Manzano, C.; Holash, J.; Fueyo, J.; Xu, J.; Conrad, CA.; Aldape, KD.; De Groot, JF.; Bekele, BN.; Yung, WK. VEGF Trap induces antiglioma effect at different stages of disease. Neuro Oncol., 2008, 10, 940-945.
45. Hu, L.; Hofmann, J.; Holash, J.; Yancopoulos, GD.; Sood, AK.; Jaffe, RB. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res., 2005, 11, 6966-6971.
46. Jin, K.; Shen, Y.; He, K.; Xu, Z.; Li, G.; Teng, L. Aflibercept (VEGF Trap): one moredouble-edged sword of anti-VEGF therapy for cancer? Clin Transl Oncol., 2010, 12, 526-532.
47. Kabbinavar, F.; Hurwitz, HI.; Fehrenbacher, L.; Meropol, NJ.; Novotny, WF.; Lieberman, G.; Griffing, S.; Bergsland, E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol., 2003, 21, 60-65.
48. Sandler, A.; Gray, R.; Perry, MC. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med., 2006, 355, 2542-2550.
49. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, EA.; Shenkier, T.; Cella, D.; Davidson, NE. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. 2007, 357, 2666-2676.
50. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic. Colorectal cancer, 2004, 350, 2335-42.
51. Escudier, B.; Eisen, T.; Stadler, WM. Sorafenib in advanced clearcell renal-cell carcinoma. N Engl J Med., 2007, 356,125-134.
52. Motzer, RJ.; Hutson, TE.; Tomczak, P. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med., 2007, 356,115-124.
53. Leighl, NB.; Raez, LE.; Besse, B.; Rosen, PJ.; Barlesi, F.; Massarelli, E.; Gabrail, N.; Hart, LL.; Albain, KS.; Berkowitz, L.; Melnyk, O.; Shepherd, FA.; Sternas, L.; Ackerman, J.; Shun, Z.; Miller, VA.; Herbst, RS. A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum-and erlotinibresistant adenocarcinoma of the lung. J Thorac Oncol., 2010, 5, 1054-1059.
54. De Groot, JF.; Lamborn, KR.; Chang, SM.; Gilbert, MR.; Cloughesy, TF.; Aldape, K.; Yao, J.; Jackson, EF.; Lieberman, F.; Robins, HI.; Mehta, MP.; Lassman, AB.; Deangelis, LM.; Yung, WK.; Chen, A.; Prados, MD.; Wen, PY. Phase II study of aflibercept in recurrent malignant glioma: a North American brain tumor consortium study. J Clin Oncol., 2011, 29, 2689-2695.
55. Wang, T.F.; Lockhart, A. C. Aflibercept in the Treatment of Metastatic Colorectal Cancer. Clin Med Insights Oncol., 2012, 6, 19-30.
56. Sanofi-Aventis; Regeneron Pharmaceuticals. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00519285. NLM Identifier: NCT00519285.
57. Koch, S.; Tugues, S.; Li, X.; Gualandi, L.; Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011, 437, 169-183.
58. Holash, J.; Maisonpierre, PC.; Compton, D.; Boland, P.; Alexander, CR.; Zagzag, D.; Yancopoulos, GD.; Wiegand, SJ. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science., 1999, 284, 1994-1998.
59. Kadenhe-Chiweshe, A.; Papa, J.; McCrudden, KW.; Frischer, J.; Bae, JO.; Huang, J.; Fisher, J.; Lefkowitch, JH.; Feirt, N.; Rudge, J.; Holash, J.; Yancopoulos, GD.; Kandel, JJ.; Yamashiro, DJ. Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res., 2008, 6, 1-9.
60. Le, XF.; Mao, W.; Lu, C.; Thornton, A.; Heymach, JV.; Sood, AK.; Bast, RC Jr. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle., 2008, 7, 3747-3758.
61. Wachsberger, PR.; Burd, R.; Cardi, C.; Thakur, M.; Daskalakis, C.; Holash, J.; Yancopoulos, GD.; Dicker.; AP. VEGF trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol Phys., 2007, 67, 1526-37.
62. Kuhnowski, F.; Thieblemont, C.; Jardin, F. A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma. J Clin Oncol., 2010, 28, 1-26.
63. Freyer, G.; Fumoleau, P.; You, B.; Isambert, N.; Chevalier, P.; Trillet-Lenoir, V. A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus docetaxel (D) and cisplatin (C) in patients (pts) with advanced solid tumors. J Clin Oncol., 2008, 26, 20-50.
64. Limentani, SA.; Just, R.; Purdham, A. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol., 2008, 26, 1-17.
65. Patnaik, A.; Pipas, M.; Rosen, L. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF Trap) plus weekly gemcitabine (Gem) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol., 2008, 26, 1-32.
66. Van Cutsem, E.; Khayat, D.; Verslype, C.; Billemont, B.; Tejpar, S.; Meric, JB.; Soussan-Lazard, K.; Assadourian, S.; Cartot-Cotton, S.; Rixe, O. A phase I dose escalation (DE) and pharmacokinetics (PK) study of intravenous aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin (I-LV5FU2) in patients with advanced solid tumors (STs). J Clin Oncol., 2012, 26, 1-8.
67. Freyer, G.; Isambert, N.; You, B.; Zanetta, S.; Falandry, C.; Favier, L.; Trillet-Lenoir, V.; Assadourian, S.; Soussan-Lazard, K.; Ziti-Ljajic, S.; Fumoleau, P. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol., 2008, 26, 598-604.
68. Verslype, C.; Spano, J.; Van Cutsem, E.; Grapin, J. P.; Vandecaveye, V.; Bloch, J.; Soussan Lazard, K.; Assadourian, S.; Tejpar, S.; Khayat, D. Validation of the selected dose of aflibercept (VEGF Trap) plus irinotecan, 5-fluorouracil, and leucovorin in a phase I clinical trial of patients (pts) with advanced solid tumors. J Clin Oncol., 2008, 26, 1-15.
69. Coleman, RL.; Duska, LR.; Ramirez, PT.; Heymach, JV.; Kamat, AA.; Modesitt, SC.; Schmeler, KM.; Iyer, RB.; Garcia, ME.; Miller, DL.; Jackson, EF.; Ng, CS.; Kundra, V.; Jaffe, R.; Sood, AK. Phase II multi-institutional study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol., 2011, 29, 1109-1117.
70. Colombo, N.; Mangili, G.; Mammoliti, S.; Kalling, M.; Tholander, B.; Sternas, L.; Buzenet, G.; Chamberlain, D. Aflibercept for advanced epithelial ovarian cancer (EOC) patients with symptomatic malignant ascites: preliminary results of a pilot study. J Clin Oncol., 2008, 26, 1-15.
71. Twardowski, P.; Stadler, WM.; Frankel, P.; Lara, PN.; Ruel, C.; Chatta, G.; Heath, E.; Quinn, DI.; Gandara, DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology., 2010, 76, 923-926.
72. Gotlieb, WH.; Amant, F.; Advani, S.; Goswami, C.; Hirte, H.; Provencher, D.; Somani, N.; Yamada, SD.; Tamby, JF.; Vergote, I. Intravenous aflibercept in advanced ovarian cancer patients with recurrent symptomatic malignant ascites: key efficacy and safety results of a phase II, randomized, double-blind, placebo-controlled study. Eur Soc Gyne Oncol., 2009, 154-162.
73. Sherman, E. J.; Ho A, L.; Haque, S.; Ghossein, R. A.; Lisa, D. M.; Schöder, H.; Baum, M. S.; Shaha A. R.; Tuttle, R. M.; Pfister, D. G. A phase II study of VEGF trap (aflibercept) in patients with radioactive iodine refractory, positron emission tomography (PET) positive thyroid carcinoma. J Clin Oncol., 2010, 28, 1-20.
74. Tang, P.; Cohen, SJ.; Bjarnason, GA.; Kollmannsberger CVirik, K.; MacKenzie, MJ.; Lourenco, L.; Wang, L.; Chen, A.; Moore, MJ. Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): a PMH phase II consortium trial. J Clin Oncol., 2008, 26, 15-21.
75. Tarhini, AA.; Frankel, P.; Margolin, KA.; Christensen, S.; Ruel, C.; Shipe-Spotloe, J.; Gandara, DR.; Chen, A.; Kirkwood, JM. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. J Clin Oncol., 2011, 17, 6574-6581.
76. Mackay, HJ.; Buckanovich, RJ.; Hirte, H.; Correa, R.; Hoskins, P.; Biagi, J.; Martin, LP.; Fleming, GF.; Morgan, R.; Wang, L.; Polintan, R.; Oza, AM. A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynaecologic carcinosarcomas and uterine leiomyosarcoma. J Clin Oncol., 2012, 125, 136-140.
77. Eastern Cooperative Oncology Group; National Cancer Institute (NCI). VEGF Trap in treating patients with metastatic or unresectable kidney cancer. In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00357760. NLM Identifier: NCT00357760.
78. Gynecologic Oncology Group; National Cancer Institute (NCI). VEGF Trap in treating patients with recurrent or persistent endometrial cancer. In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00462826. NLM Identifier: NCT00462826.
79. Weill Medical College of Cornell University; National Cancer Institute (NCI). VEGF Trap in treating patients with stage II or stage III multiple myeloma that has relapsed or not responded to previous treatment. In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00437034. NLM Identifier: NCT00437034.
80. California Cancer Consortium; National Cancer Institute (NCI), Aflibercept in treating patients with myelodysplastic syndromes. In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00509249. NLM Identifier: NCT00509249.
81. Sanofi-Aventis; Regeneron Pharmaceuticals. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00519285. NLM Identifier: NCT00519285.
82. Riess H, Manges R, Karasek P. Double-blind, placebo-controlled randomized phase III trial of aflibercept (A) plus gemcitabine (G) versus placebo (P) plus gemcitabine (G) in patients with metastatic pancreatic cancer: Final results. In: Proceedings from the 12th world congress on gastrointestinal cancer. June 30-July 3, 2010; Barcelona, Spain. Abstract O-0006.
83. Sanofi-Aventis; Regeneron Pharmaceuticals. A study of aflibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL). In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00532155. NLM Identifier: NCT00532155.
84. Novello S, Ramlay R, Gorbunova VA. Aflibercept in combination with docetaxel for second-line treatment of locally advanced or metastatic nonsmall-cell lung cancer (NSCLC): Final results of a multinational placebo controlled phase III trial (EFC10261-VITAL). In: Proceedings from the international association for the study of lung cancer. July 3-7, 2011; Amsterdam, The Netherlands. Abstract O43.06.
85. Sanofi-Aventis; Regeneron Pharmaceuticals, National Surgical Adjuvant Breast and Bowel Project (NSABP). Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). In: ClinicalTrials. gov Internet. Bethesda (MD): National Library of Medicine (US); 2000 [cited 2011 October 7]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00561470. NLM Identifier: NCT00561470.
86. Van Cutsem E, Tabernero J, Lakomy R. Intravenous Aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational Phase III trial (EFC10262-VELOUR). Ann Oncol., 2011, 22(s5) abstract O-0024.
87. Carmen, JA.; Radek, L.; Josep, T.; Jana, P.; Paul, R.; Guy, VH.; Vladimir, MM.; David, RF.; Joseph, JM.; Eric, VC. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. J Clin Oncol., 30, 2012 abstract 3505.